DC-CIK细胞疗法联合干扰素治疗慢性乙肝临床研究

Therapeutic effect of DC-CIK cell therapy combined with interferon on chronic hepatitis B

目的观察DC-CIK细胞疗法联合干扰素对慢性乙型肝炎的治疗效果。方法 134例CHB患者随机分成治疗组(DC-CIK细胞疗法联合干扰素)50例和对照组(干扰素)84例,观察2组患者肝功能、HBV-DNA、HBeAg的变化,同时观察治疗组3个月和6个月时患者肝功能、HBV-DNA、HBeAg的变化。结果治疗组HBV-DNA转阴率与对照组差异无统计学意义(P>0.05),治疗组HBeAg阴转率(56%)、抗-HBe阳转率(40%)以及ALT复常率(88%)均明显高于对照组(分别为38.1%、19.1%、57.1%),治疗组治疗6个月时,其HBV-DNA转阴率(48%)、HBeAg转阴率(56%)、抗-HBe阳转率(40%)以及ALT复常率(88%)均明显高于治疗3个月时(分别为24%、32%、18%、70%),差异有统计学意义(P<0.05)。结论 DC-CIK细胞疗法联合干扰素治疗慢性乙肝较单用干扰素疗效更佳。

Objective To observe the therapeutic effect of DC-CIK cell therapy combined with interferon（IFN-α）on chronic hepatitis B（CHB）.Methods A total of 134 patients with chronic hepatitis B were randomly divided into treatment group（DC-CIK cell therapy combined with IFN α）and control group（IFN α only）,and the patients＇liver function,HBV-DNA levels and HBV markers were detected after treatment.Results There was no significant difference in the negative rate of HBV DNA between treatment group and control group（P〈0.05）,however,the negative rate of HBeAg,anti-Hbe seroconversion rate and ALT normalization rate in treatment group was remarkably increased,as compared with those in control group（P〈0.05）.After 6-month treatment,the negative rate of HBV DNA,negative rate of HBeAg,anti-Hbe seroconversion rate and ALT normalization rate in treatment group was significantly increased,as compared with those after 3-month treatment（P〈0.05）.Conclusion The DC-CIK cell therapy combined with IFN α is superior to IFN α only in the treatment of chronic hepatitis B.